In early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem. Novartis' prostate cancer therapy Pluvicto, released only the year before, was suddenly in short supply, snarling up just in time treatment schedules.

In 2024 the supply chain problem is with the isotope Actinium 225, which *everyone* wants for clinical trials. RayzeBio has been a very famous victim, delaying a clinical trial because of the shortages.

In episode 3 of Nuked we explore where the nukes come from, and how biotechs large and small get their hands on them.

With GlyTherix CEO Dr Brad Walsh and Telix Pharmaceuticals CEO Dr Chris Behrenbruch, we look at a potential new front in the US-China tariff war, the Russia question, and how an early stage biotech and one with a product in the market organises its nuclear material supplies.

Support the show

The radiopharmaceuticals sector is on a knife point. The scope of what nuclear medicine can do is exploding. But the radioisotopes that biotechs need to make those therapies are in very, very short supply. Major clinical trials are hitting pause because of shortages of critical nuclear isotopes, and the world's biggest pharmaceutical companies are buying up biotechs that have locked in both the science and the supply chain.

There will be some very successful winners, and many, many losers as companies fight for the nuclear resources they so desperately need to make their therapies work.

In this series Nuked, we will walk you through this fascinating marriage between chemistry and physics, why is exciting both investors and clinicians, how biotechs are fighting to lock in supplies of nuclear material, and whether Australia has a shot at becoming a nuclear power.

In our first episode, we speak to Peter MacCallum Cancer Center chief radiopharmaceutical scientist Dr Mohammad Haskali and HB Biotechnology managing director Charlie Williams.

Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.

Support the show

Wearable kidneys. Organs on a chip. Xenotransplantation. The future is here.

But is that the future people in biotech are truly looking to? Because the future that Certa Therapeutics CEO Darren Kelly is looking to is much less 1980s sci-fi and more... Apple watch.

And in a future where the numbers point to a rise in lifestyle diseases thanks to diet and a lack of exercise, climate change is an added risk that few are yet factoring in. Professor Meg Jardine, the head of University of Sydney's Clinical Trials Centre, explains where the risks are.

Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.

Support the show

We may have led you on a bit in the first two episodes... kidney disease is still a big problem despite the massive shifts forward in treating it. There is a long way to go to bring medical sectors -- and governments -- along as well.

This episode features Breonny Robson, general manager of clinical and research at Kidney Health Australia and Richard Lipscombe, managing director of Proteomics International.

Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.

Support the show

We speak to Dimerix CEO Dr Nina Webster about why investors are thrilled with her company, as it nears the midway point for its Phase III clinical trial for the rare disease focal segmental glomerulosclerosis (FSGS).

And we talk to PYC Therapeutics CEO Dr Rohan Hockings about how his company's tech actually works to treat polycystic kidney disease.

Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.

Support the show

Kidney disease is a silent killer, with only 10% of all people knowing they have it before damage has been done.

But in the last five years there's been a surge of work that's resulted in the FDA approving some blockbuster drugs in the last 18 months. Billion-dollar takeovers are now on the table and the tiny number of Australian biotechs in this sector have a front row seat to the action.

This series explains the mighty leaps that have already come, interviews the key biotech leaders in Australia working to treat and to cure kidney diseases, and joins the dots between what is happening today… and what could happen in the blue skies of the next 20 to 50 years.

Episode 1 features Professor Meg Jardine, director of the NHMRC Clinical Trials Centre, a flagship research organisation at the University of Sydney, where she is head of the Kidney Health research program, and investment analyst Chris Kallos. They explain why kidney disease is so hot right now from a science perspective and for investors.

Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.

Support the show

Life sciences more than anywhere else is the successful mashup of money and tech.

I'm Rachel Williamson and this is Phase III, a weekly podcast diving deep into Australian life sciences. In each of our short series, we investigate, interrogate, and explore the most exciting companies and ideas in health science and the investment case for what they're doing. Join us as we explore the intersection between the breakthroughs and the money in life sciences.

Support the show